[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331054-105":59,"doc-detail-331054-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multiyear-clinical-outcomes-of-cancers-diagnosed-following-detection-by-a-blood-based-multicancer-early-detection-test","Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection Test","","Multiyear clinical outcomes are reported for cancers diagnosed after a positive blood-based multicancer early detection test (CancerSEEK) in the prospective DETECT-A trial. Among 26 participants, nine cancer types were detected initially by CancerSEEK and information on diagnoses, treatments, and outcomes was extracted from medical records through November 2022. Median follow-up was 4.4 years, with 50% alive and cancer-free; surgical and treated early-stage participants showed favorable multiyear results and eligibility for surgery correlated with improved outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multiyear-clinical-outcomes-of-cancers-diagnosed-following-detection-by-a-blood-based-multicancer-early-detection-test/331054/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multiyear-clinical-outcomes-of-cancers-diagnosed-following-detection-by-a-blood-based-multicancer-early-detection-test/331054.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the DETECT-A study and what test does it evaluate?","Question",{"text":112,"@type":113},"DETECT-A is a prospective interventional trial evaluating an MCED blood test (CancerSEEK). It enrolled participants from 2017 to 2019 and used diagnostic PET-CT to identify cancers, including those not detected by standard-of-care screening.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many participants and cancer types were diagnosed after a positive CancerSEEK test?",{"text":117,"@type":113},"Nine cancer types were diagnosed in 26 participants whose cancers were first detected by CancerSEEK.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key multiyear outcome findings reported in the study?",{"text":121,"@type":113},"At a median of 4.4 years follow-up, 50% of participants (13/26) were alive and cancer-free. Early-stage treated participants showed strong cancer-free outcomes, and eligibility for surgical treatment was associated with favorable multiyear results.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331054,1790217094,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection Test  \nAdam H. Buchanan1, Anne M. Lennon2, Omair A. Choudhry3, Paul Z. Elias3, Seema P. Rego3, Jennifer R. Sadler3, Julia Roberta3, Yongqiang Zhang3, Darl D. Flake II3, Zachary M. Salvati1, Eric S. Wagner1, Elliot K. Fishman4, Nickolas Papadopoulos4, and Tomasz M. Beer3  \n|  |  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 􀀶 |  | In the US, \u003C20% of cancers are diagnosed by standard-ofcare (SoC) screening. Multicancer early detection (MCED) tests offer the opportunity to expand cancer screening. Understanding the characteristics and clinical outcomes of MCED-detected cancers is critical to clarifying MCED tests’potential impact. DETECT-A is the first prospective interventional trial of an MCED blood test (CancerSEEK). CancerSEEK, coupled with diagnostic PET-CT, identified cancers including those not detected by SoC screening, the majority of which were localized or regional. We report multiyear outcomes in patients with cancers diagnosed following a positive CancerSEEK test. Nine cancer types were diagnosed in 26 participants whose cancers were first detected by CancerSEEK. Information on cancer diagnoses, treatments, and clinical outcomes was extracted from medical records through November 2022. Data collection occurred at a median of 4.4 years (IQR: 4.1–4.6) following study enrollment. Thirteen of 26 (50%) participants were alive and cancer-free [ovarian (4), thyroid (1), uterine (2), breast (1), colorectal (2), and lung (3)]; 7/13 (54%) had cancers without recommended |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | SoC screening modalities. All eight treated stage I or II participants (8/8, 100%) and 12/14 (86%) surgically treated participants were alive and cancer-free. Eligibility for surgical treatment was associated with favorable multiyear outcomes (P ¼ 0.0002). Half of participants with MCED-detected cancers were alive and cancer-free after 4.4 years median follow-up. Most were diagnosed with early-stage cancers and were treated surgically. These results suggest that early cancer detection by CancerSEEK may have facilitated curative-intent treatments and associated positive clinical outcomes in some DETECT-A participants.\u003Cbr>Prevention Relevance: This study provides preliminary evidence of the potential of multicancer early detection testing as an effective screening tool for detecting cancers without standard-of-care (SoC) screening modalities and complementing SoC cancer screening.\u003Cbr>Watch the interview with Tomasz M. Beer, MD, recipient of the 2026 Cancer Prevention Research Award for Outstanding Journal Article: [https://vimeo.com/1208911576](https://vimeo.com/1208911576) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nGuideline-endorsed standard-of-care (SoC) cancer screening tests are available for only a few cancer types (1–5); most i","cbCaidlwKUIlsi2M","https://ap.wps.com/l/cbCaidlwKUIlsi2M","pdf",873204,"English","# Introduction\n## Standard-of-care screening limitations\n## Rationale for blood-based MCED tests\n# DETECT-A study design and participants\n## Cancer detection approach with CancerSEEK and PET-CT\n## Outcome assessment and follow-up timing","[{\"question\":\"What is the DETECT-A study and what test does it evaluate?\",\"answer\":\"DETECT-A is a prospective interventional trial evaluating an MCED blood test (CancerSEEK). It enrolled participants from 2017 to 2019 and used diagnostic PET-CT to identify cancers, including those not detected by standard-of-care screening.\"},{\"question\":\"How many participants and cancer types were diagnosed after a positive CancerSEEK test?\",\"answer\":\"Nine cancer types were diagnosed in 26 participants whose cancers were first detected by CancerSEEK.\"},{\"question\":\"What were the key multiyear outcome findings reported in the study?\",\"answer\":\"At a median of 4.4 years follow-up, 50% of participants (13/26) were alive and cancer-free. Early-stage treated participants showed strong cancer-free outcomes, and eligibility for surgical treatment was associated with favorable multiyear results.\"}]","Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection Test | PDF",1789991381,13]